PDCD1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: (34) found that in patients with advanced/metastatic Xp11.2 tRCC treated with VEGFR-TKI (axitinib) and a PD-1 inhibitor (pembrolizumab) as first-line therapy, the treatment was effective, with a median progression-free survival of more than 16.6 months and a median overall survival of more than 25.6 months, with the disease remaining progression-free.